1,2,4-Triazole-based anticonvulsant agents with additional ROS scavenging activity are effective in a model of pharmacoresistant epilepsy

References

• Behr C, Goltzene MA, Kosmalski G, et al. Epidemiology of epilepsy. Rev Neurol 2016;172:27–36.
   PubMedGoogle Scholar
• Harman D. The biologic clock: the mitochondria?. J Am Geriatr Soc 1972;20:145–7.
   PubMed Web of Science ®Google Scholar
• Pearson-Smith JN, Patel M. Metabolic dysfunction and oxidative stress in epilepsy. Int J Mol Sci 2017;18:2365.
   Web of Science ®Google Scholar
• Aguiar CCT, Almeida AB, Araujo PVP, et al. Oxidative stress and epilepsy: literature review. Oxid Med Cell Longev 2012;2012:1–12. article ID 795259.
   Web of Science ®Google Scholar
• Patel M. Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizures. Free Radic Biol Med 2004;37:1951–62.
   PubMed Web of Science ®Google Scholar
• Dingledine R, Varvel NH, Dudek FE. When and how do seizures kill neurons, and is cell death relevant to epileptogenesis? Adv Exp Med Biol 2014;813:109–22.
   PubMed Web of Science ®Google Scholar
• Grewal GK, Kukal S, Kanojia N, et al. Effect of oxidative stress on ABC transporters: contribution to epilepsy pharmacoresistance. Molecules 2017;22:365.
   Web of Science ®Google Scholar
• Behrend L, Henderson G, Zwacka R. Molecular mechanisms of signalling molecular mechanisms of signalling transformation. Biochem Soc Trans 2003;31:1441–4.
   PubMed Web of Science ®Google Scholar
• Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia 2018;59:2179–93.
   PubMed Web of Science ®Google Scholar
• Kaproń B, Łuszczki JJ, Siwek A, et al. Preclinical evaluation of 1,2,4-triazole-based compounds targeting voltage-gated sodium channels (VGSCs) as promising anticonvulsant drug candidates. Bioorg Chem 2020;94:103355.
   PubMed Web of Science ®Google Scholar
• Kaproń B, Łuszczki JJ, Płazińska A, et al. Development of the 1,2,4-triazole-based anticonvulsant drug candidates acting on the voltage-gated sodium channels. Insights from in-vivo, in-vitro, and in-silico studies. Eur J Pharm Sci 2019;129:42–57.
   PubMed Web of Science ®Google Scholar
• Kaproń B, Łuszczki J, Paneth A, et al. Molecular mechanism of action and safety of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione – a novel anticonvulsant drug candidate. Int J Med Sci 2017;14:741–9.
   PubMed Web of Science ®Google Scholar
• Plech T, Luszczki JJ, Wujec M, et al. Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1,2,4-triazoles. Eur J Med Chem 2013;60:208–15.
   PubMed Web of Science ®Google Scholar
• Plech T, Kaproń B, Łuszczki JJ, et al. Studies on the anticonvulsant activity of 4-alkyl-1,2,4-triazole-3-thiones and their effect on gabaergic system. Eur J Med Chem 2014;86:690–9.
   PubMed Web of Science ®Google Scholar
• Plech T, Kaproń B, Łuszczki JJ, et al. Studies on the anticonvulsant activity and influence on GABA-ergic neurotransmission of 1,2,4-triazole-3-thione-based compounds. Molecules 2014;19:11279–99.
   PubMed Web of Science ®Google Scholar
• Łuszczki JJ, Marzeda P, Gut-Lepiech A, et al. New derivative of 1,2,4-triazole-3-thione (TP427) potentiates the anticonvulsant action of valproate, but not that of carbamazepine, phenytoin or phenobarbital in the mouse tonic-clonic seizure model. Pharmacol Rep 2019;71:299–305.
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Patrzylas P, Zagaja M, et al. Effects of arachidonyl-2’-chloroethylamide (ACEA) on the protective action of various antiepileptic drugs in the 6-Hz corneal stimulation model in mice. PLoS One 2017;12:e0183873.
   PubMed Web of Science ®Google Scholar
• Litchfield JT, Jr, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99–113.
   PubMed Web of Science ®Google Scholar
• Kapron B, Czarnomysy R, Paneth A, et al. Dual antibacterial and anticancer activity of 4-benzoyl-1-dichlorobenzoylthiosemicarbazide derivatives. Anticancer Agents Med Chem 2018;18:529–40.
   PubMed Web of Science ®Google Scholar
• Apak R, Güçlü K, Özyürek M, et al. Mechanism of antioxidant capacity assays and the CUPRAC (cupric ion reducing antioxidant capacity) assay. Microchim Acta 2008;160:413–9.
   Web of Science ®Google Scholar
• Krasavin M, Žalubovskis R, Grandāne A, et al. Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase. J Enzyme Inhib Med Chem 2020;35:506–10.
   PubMed Web of Science ®Google Scholar
• Küçükbay H, Buğday N, Küçükbay FZ, et al. Synthesis and human carbonic anhydrase I, II, VA, and XII inhibition with novel amino acid–sulphonamide conjugates. J Enzyme Inhib Med Chem 2020;35:489–97.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Gorecki L, Andrys R, Schmidt M, et al. Cysteine-targeted insecticides against A. gambiae acetylcholinesterase are neither selective nor reversible inhibitors. ACS Med Chem Lett 2020;11:65–71.
   PubMed Web of Science ®Google Scholar
• Barton ME, Klein BD, Wolf HH, et al. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47:217–27.
   PubMed Web of Science ®Google Scholar
• Potschka H. Animal models of drug-resistant epilepsy. Epileptic Disord 2012;14:226–34.
   PubMed Web of Science ®Google Scholar
• Metcalf CS, West PJ, Thomson KE, et al. Development and pharmacologic characterization of the rat 6 Hz model of partial seizures. Epilepsia 2017;58:1073–84.
   PubMed Web of Science ®Google Scholar
• Stables JP, Bertram E, Dudek FE, et al. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia 2003;44:1472–8.
   PubMedGoogle Scholar
• White HS, Smith-Yockman M, Srivastava A, et al. Therapeutic assays for the identification and characterization of an-tiepileptic and antiepileptogenic drugs. In: Pitkänen A, Schwartzkroin PA, MoshØ SL, eds. Models of seizures and epilepsy. Amsterdam: Elsevier; 2006:539–549.
   Google Scholar
• Löscher W, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res 1991;9:1–10.
   PubMed Web of Science ®Google Scholar
• Folbergrova J, Kunz WS. Mitochondrial dysfunction in epilepsy. Mitochondrion 2012;12:35–40.
   PubMed Web of Science ®Google Scholar
• Jarrett SG, Liang LP, Hellier JL, et al. Mitochondrial DNA damage and impaired base excision repair during epileptogenesis. Neurobiol Dis 2008;30:130–8.
   PubMed Web of Science ®Google Scholar
• Callaway JK, Beart PM, Jarrott B, et al. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol 2001;132:1691–8.
   PubMed Web of Science ®Google Scholar
• Callaway JK, Castillo-Melendez M, Giardina SF, et al. Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence. Neuropharmacology 2004;47:146–55.
   PubMed Web of Science ®Google Scholar
• Callaway JK, Knight MJ, Watkins DJ, et al. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats. Stroke 1999;30:2704–12.
   PubMed Web of Science ®Google Scholar
• Kolosov A, Goodchild CS, Cooke I. Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. Pain Med 2010;11:106–18.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother 2015;15:851–6.
   PubMed Web of Science ®Google Scholar
• Provensi G, Carta F, Nocentini A, et al. A new kid on the block? Carbonic anhydrases as possible new targets in Alzheimer’s disease. Int J Mol Sci 2019;20:4724.
   PubMed Web of Science ®Google Scholar
• Sun MK, Zhao WQ, Nelson TJ, et al. Theta rhythm of hippocampal CA1 neuron activity: gating by GABAergic synaptic depolarization. J Neurophysiol 2001;85:269–79.
   PubMed Web of Science ®Google Scholar
• Sun MK, Alkon DL. Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats. J Pharmacol Exp Ther 2001;297:961–7.
   PubMed Web of Science ®Google Scholar
• Yang MT, Chien WL, Lu DH, et al. Acetazolamide impairs fear memory consolidation in rodents. Neuropharmacology 2013; 67:412–8.
   PubMed Web of Science ®Google Scholar
• Shank RP, Doose DR, Streeter AJ, et al. Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res 2005;63:103–12.
   PubMed Web of Science ®Google Scholar
• Thompson PJ, Baxendale SA, Duncan JS, et al. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69:636–41.
   PubMed Web of Science ®Google Scholar